Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709097 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL9169189 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL27869350 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL455480 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL7857041 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL10810735 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL8165832 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL2648008 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL10370405 | 1.00 | CYP3A4 (0.48) | CYP3A4TDP1CES2CES1KCNH2 | |
| SCHEMBL4067213 | 0.98 | CYP3A4 (0.50) | CYP3A4TDP1CES2CES1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170367989-A1 | NANOPARTICLES FOR LIPID HOMEOSTASIS | NATIONAL INSTITUTES OF HEALTH | 2017-12-28 | — | — | US | disclosed |
| EP-3236955-A1 | NANOPARTICLES FOR LIPID HOMEOSTASIS | University of Georgia Research Foundation Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106328-A1 | NANOPARTICLES FOR LIPID HOMEOSTASIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| CN-105477633-A | Hypocrellin cationic liposome preparation and preparation method and application thereof | FIRST AFFILIATED HOSPITAL CHINESE PLA GENERAL HOSPITAL | 2016-04-13 | — | — | CN | disclosed |
| US-20070142657-A1 | Process for the preparation of aliphatic primary alcohols and intermediates in such process | DSM IP ASSETS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| EP-1685089-A1 | PROCESS FOR THE PREPARATION OF ALIPHATIC PRIMARY ALCOHOLS AND INTERMEDIATES IN SUCH PROCESS | DSM IP Assets B.V. (NL) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047221-A1 | PROCESS FOR THE PREPARATION OF ALIPHATIC PRIMARY ALCOHOLS AND INTERMEDIATES IN SUCH PROCESS | DSM IP ASSETS B.V. (NL) | 2005-05-26 | — | — | WO | disclosed |
| US-5446189-A | Diester intermediates for diacid enzyme inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5324747-A | Treatment of inflammatory diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0579066-A2 | N-substituted anilines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170367989-A1 | NANOPARTICLES FOR LIPID HOMEOSTASIS | LDLR, APOB, HDLBP | CYP3A4 3109/4885TDP1 1555/4885CES2 1650/4885 |
| US-20070142657-A1 | Process for the preparation of aliphatic primary alcohols and intermediates in such process | CYP2E1, MSMO1, ADH1C | CYP3A4 225/4885TDP1 4711/4885CES2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.